Publications by authors named "H Bote"
Article Synopsis
- Butylated Hydroxytoluene (BHT), commonly used as an antioxidant in food, causes cellular toxicity by inducing oxidative stress and increasing reactive oxygen and nitrogen species (ROS and RNS).
- The herbal compounds Boeravinone B (BB) and Chebulinic acid (CA), when combined, showed significant protective effects against BHT’s toxicity by reducing levels of ROS and RNS, as well as decreasing enzymes and markers associated with oxidative stress.
- The treatment with BB and CA effectively reduced apoptosis and autophagy in cells exposed to BHT, promoting cell growth and suggesting their potential use as therapeutic agents for conditions related to oxidative stress-induced liver damage.
Article Synopsis
- Erdheim-Chester disease (ECD) is a rare condition that can present in diverse ways, including bone pain and osteosclerosis, making awareness crucial for early diagnosis.
- * A 50-year-old man from Ethiopia with a long history of symptoms was diagnosed after specific imaging and histological tests revealed classic signs of ECD.
- * Clinicians should recognize the characteristic features of ECD in patients with unexplained bone pain to ensure timely treatment and management of potential complications.
Introduction: Dog bites are a common presentation in emergency departments. However, scrotal injuries with complete testicular avulsion are exceedingly rare.
Case Presentation: We present a case of a dog bite to the scrotum with complete detachment of the testis and right hemiscrotum in an intoxicated 48-year-old man, who was treated with wound irrigation, debridement, antibiotic prophylaxis, tetanus and rabies vaccination, and a covering scrotoplasty.
Purpose: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC.
Experimental Design: We analyzed tumor samples from 58 patients with ES-SCLC enrolled in two multicenter single-arm phase IIIb studies evaluating frontline chemoimmunotherapy in Spain: n = 32 from the IMfirst trial and n = 26 from the CANTABRICO trial.